A carregar...
1355. Global Activity of Imipenem–Relebactam and Comparators Against Clinical Gram-Negative Pathogens – SMART 2017
BACKGROUND: Relebactam (REL), formerly MK-7655, is a β-lactamase inhibitor of class A and C β-lactamases that is in development in combination with imipenem (IMI). In this study, we evaluated the activity of IMI/REL against recent clinical isolates of Gram-negative bacilli (GNB) collected globally a...
Na minha lista:
Publicado no: | Open Forum Infect Dis |
---|---|
Main Authors: | , , , , , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
Oxford University Press
2018
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6252988/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofy210.1186 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|